1National Medical Center, Center for Public Healthcare Support, Seoul, Korea
2National Cancer Control Institute, National Cancer Center, Goyang, Korea
Copyright © 2020 The Korean Society for Preventive Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST
The authors have no conflicts of interest associated with the material presented in this paper.
FUNDING
This work was supported by the National Cancer Center (grant No.1610311).
AUTHOR CONTRIBUTIONS
Conception and design: HSM, YAK. Acquisition of data: HSM, JP. Formal analysis: HSM. Funding acquisition: YAK. Writing - original draft: HSM. Writing - review & editing: EHY, JP, YAK.
Newspaper | n (%) |
---|---|
Kyunghyang Shinmun | 284 (10.1) |
Kukmin Ilbo | 665 (23.7) |
Naeil Shinmun | 98 (3.5) |
Munhwa Ilbo | 117 (4.2) |
Seoul Shinmun | 395 (14.1) |
Segye Ilbo | 510 (18.2) |
Chosun Ilbo | 307 (10.9) |
Hankyoreh | 128 (4.6) |
Hankook Ilbo | 302 (10.8) |
Total | 2806 (100) |
Theme | Main content and examples | Articles, n (%) | |
---|---|---|---|
General healthcare information | Healthcare or medical information about cancer prevention, risk factors, diagnosis, treatment, prognosis, or patient management | 816 (29.1) | |
“If the necessary tests are not performed or treatment is delayed, it can lead to severe consequences. Now take a look at the proper tests and diagnostic methods for thyroid cancer together with Chief [name] of [hospital] in [region]…” (Naeil Shinmun; September 20, 2016) | |||
“In stage 3 cancer, the cancer detected in one or both ovaries is found, histologically, to have metastasized to an extrapelvic part of the abdominal cavity or to the retroperitoneal lymph nodes… New blood vessels form as vascular endothelial growth factor (VEGF) secreted by cancer cells binds to VEGF receptors on the surface of vascular endothelial cells” (Kukmin Ilbo; April 3, 2016) | |||
Latest research and development | News about the latest published research, or development of technology and products | 629 (22.4) | |
“The research teams of professor [name] in [hospital name] and professor [name] in [research institute name] have, for the first time, devised a new anticancer strategy suitable for patients’ genetic characteristics. This research paper was featured on the cover of the latest issue of the renowned international journal, [journal name]…The team said that this will be an important step towards gene-based, customizable cancer treatment for individual patients” (Chosun Ilbo; September 16, 2015) | |||
Specific medical institutions/personnel | Issues relating to information about specific medical institutions or personnel | 382 (13.6) | |
“[Hospital name] (Hospital Chief [name]) is one of the top cancer hospitals in Asia, leading advances and setting the standard for cancer treatment in Korea… Across 13 centers and 4 specialized centers for different types of cancer, the hospital receives 1800 outpatients and performs 50 operations per day, on average. As the first hospital to introduce a multidisciplinary approach to cancer treatment, [hospital name]… provides one-stop treatment for severe cancer patients” (Kyunghyang Shinmun; May 8, 2015) | |||
Specific technology/products | Issues relating to certain currently used services, technologies, drugs, or devices | 271 (9.7) | |
“[Pharmaceutical company name] revealed that they had launched [drug name], an adjuvant oral medication for use in anticancer therapy… this product is harmless if swallowed, so it is effective at treating esophageal disorders caused by mouth sores… After rinsing the whole oral cavity for 1 minute with a dose of 5-10 mL, the medication can be swallowed or spat out. This process should be repeated 4-6 times a day” (Segye Ilbo; March 19, 2016) | |||
Statistics | Statistics published at the national or institutional level | 175 (6.2) | |
“The incidence of cancer in the whole population has declined for the last 3 years in a row, with the number of cancer patients falling below 300 persons per 100 000 population in 2014… The number of new cancer patients per 100 000 population was 323.3 persons in 2012, 314.1 persons in 2013, and 289.1 persons in 2014” (Seoul Shinmun; December 21, 2016) | |||
National policies/programs | Issues regarding cancer-related policies, institutions, and programs at the national level | 122 (4.3) | |
"The Ministry of Health and Welfare will convene the National Cancer Management Committee… In accordance with the latest general plan, starting next year, free cancer screening will be provided to 8000 individuals who have smoked one pack a day for the last 30 years, before gradually expanding the project to a broader population” (Seoul Shinmun; September 12, 2016) | |||
National Health Insurance | Issues relating to health insurance coverage and ways to reduce expenses | 122 (4.3) | |
“Although the government is trying to offer coverage for new drugs, including anticancer agents, it said to be having little effect on patient satisfaction… New anticancer drugs are the most important factor in increasing the life expectancy of stage 4 cancer patients, but the insurance coverage rate is not even one-third…” (Kukmin Ilbo; May 15, 2016) | |||
Private insurance | Information about and issues relating to private health insurance | 85 (3.0) | |
“The most common complaints at the stage of encouraging insurance registration were regarding insincere explanations and the ceremonious nature of providing a written signature. The Financial Supervisory Service pointed out that this situation arose because many insurance sales occurred via acquaintances (insurance agents), and because the insurance terms and conditions were difficult to understand for most registrants” (Hankook Ilbo; January 5, 2015) | |||
Cancer and environmental factors | Issues relating to carcinogenic factors in the surrounding environment, such as nuclear power plants or industrial facilities | 65 (2.3) | |
“Among 10 elementary, middle, or high schools fitted with urethane running tracks, lead concentrations were found to exceed the accepted threshold in 6 schools... the education authorities have been unable to prepare the required funds to remove these tracks, the schools have had no choice but to leave these carcinogen-containing tracks in place for a considerable time… There are growing voices calling for high-risk students, who have experienced high-dose or long-term exposure, to be offered health examinations” (Naeil Shinmun; July 26, 2016) | |||
Occupational cancer | Issues relating to carcinogenic factors in the workplace | 37 (1.3) | |
“The three units participating in the mediation committee discussing the issue of victims of occupational disease such as leukemia at [company name] have revealed their stance… The mediation committee plans to announce their recommendations for three matters based on the standpoints of the three bargaining unit” (Hankyoreh; January 16, 2015) | |||
Other | Other issues (including interests, disputes, corporate activities, the healthcare system, etc.) | 102 (3.6) | |
Total | 2806 (100) |
Topic | Tone | Informational | Analysis | Opinion/review | Total |
---|---|---|---|---|---|
General healthcare information | Positive | 34 (4.1) | 8 (0.9) | 5 (0.6) | 47 (5.7) |
Negative | 32 (3.9) | 22 (2.7) | 17 (2.1) | 71 (8.7) | |
Neutral | 633 (77.5) | 58 (7.1) | 7 (0.8) | 698 (85.5) | |
Total | 699 (85.6) | 88 (10.7) | 29 (3.5) | 816 (100) | |
Latest research and development | Positive | 149 (23.7) | 4 (0.6) | 0 (0.0) | 153 (24.3) |
Negative | 7 (1.1) | 0 (0.0) | 0 (0.0) | 7 (1.1) | |
Neutral | 457 (72.6) | 12 (1.9) | 0 (0.0) | 469 (74.6) | |
Total | 613 (97.4) | 16 (2.5) | 0 (0.0) | 629 (100) | |
Specific medical institutions/personnel | Positive | 310 (81.1) | 4 (1.0) | 0 (0.0) | 314 (82.2) |
Negative | 1 (0.2) | 1 (0.2) | 0 (0.0) | 2 (0.5) | |
Neutral | 66 (17.3) | 0 (0.0) | 0 (0.0) | 66 (17.3) | |
Total | 377 (98.7) | 5 (1.3) | 0 (0.0) | 382 (100) | |
Specific technology/products | Positive | 166 (61.3) | 18 (6.6) | 0 (0.0) | 184 (67.9) |
Negative | 5 (1.8) | 4 (1.5) | 2 (0.7) | 11 (4.1) | |
Neutral | 65 (23.9) | 10 (3.7) | 1 (0.4) | 76 (28.0) | |
Total | 236 (87.1) | 32 (11.8) | 3 (1.1) | 271 (100) | |
Statistics | Positive | 8 (4.6) | 3 (1.7) | 0 (0.0) | 11 (6.3) |
Negative | 2 (1.1) | 0 (0.0) | 0 (0.0) | 2 (1.1) | |
Neutral | 142 (81.1) | 20 (11.4) | 0 (0.0) | 162 (92.6) | |
Total | 152 (86.8) | 23 (13.1) | 0 (0.0) | 175 (100) | |
National policies/programs | Positive | 16 (13.1) | 2 (1.6) | 3 (2.4) | 21 (17.2) |
Negative | 5 (4.1) | 4 (3.3) | 7 (5.7) | 16 (13.1) | |
Neutral | 73 (59.8) | 10 (8.2) | 2 (1.6) | 85 (69.6) | |
Total | 94 (77.0) | 16 (13.1) | 12 (9.8) | 122 (100) | |
National Health Insurance | Positive | 15 (12.3) | 1 (0.8) | 0 (0.0) | 16 (13.1) |
Negative | 8 (6.5) | 24 (19.6) | 17 (13.9) | 49 (40.2) | |
Neutral | 46 (37.7) | 10 (8.2) | 1 (0.8) | 57 (46.7) | |
Total | 69 (56.5) | 35 (28.7) | 18 (14.7) | 122 (100) | |
Private insurance | Positive | 19 (22.4) | 1 (1.2) | 0 (0.0) | 20 (23.5) |
Negative | 4 (4.7) | 7 (8.2) | 0 (0.0) | 11 (12.9) | |
Neutral | 49 (57.6) | 5 (5.9) | 0 (0.0) | 54 (63.5) | |
Total | 72 (84.7) | 13 (15.3) | 0 (0.0) | 85 (100) | |
Cancer and environmental factors | Positive | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0) |
Negative | 10 (15.4) | 8 (12.3) | 1 (1.5) | 19 (29.2) | |
Neutral | 38 (58.4) | 8 (12.3) | 0 (0.0) | 46 (70.7) | |
Total | 48 (73.8) | 16 (24.6) | 1 (1.5) | 65 (100) | |
Occupational cancer | Positive | 1 (2.7) | 0 (0.0) | 1 (2.7) | 2 (5.4) |
Negative | 2 (5.4) | 3 (8.1) | 1 (2.7) | 6 (16.2) | |
Neutral | 24 (64.8) | 5 (13.5) | 0 (0.0) | 29 (78.4) | |
Total | 27 (72.9) | 8 (21.6) | 2 (5.4) | 37 (100) | |
Other | Positive | 46 (45.1) | 0 (0.0) | 0 (0.0) | 46 (45.1) |
Negative | 1 (0.9) | 1 (0.9) | 1 (0.9) | 3 (2.9) | |
Neutral | 49 (48.0) | 3 (2.9) | 1 (0.9) | 53 (51.9) | |
Total | 96 (94.1) | 4 (3.9) | 2 (1.9) | 102 (100) | |
Total | 2483 (88.4) | 256 (9.1) | 67 (2.3) | 2806 (100) |
Topic | No. of sources |
|||
---|---|---|---|---|
Single | Multiple (≥2) | Unclear | Total | |
General healthcare information | 422 (51.7) | 287 (35.2) | 107 (13.1) | 816 (29.1) |
Latest research and development | 546 (86.8) | 73 (11.6) | 10 (1.6) | 629 (22.4) |
Specific medical institutions/personnel | 336 (87.9) | 34 (8.9) | 12 (3.1) | 382 (13.6) |
Specific technology/products | 172 (63.4) | 63 (23.2) | 36 (13.2) | 271 (9.7) |
Statistics | 132 (75.4) | 40 (22.8) | 3 (1.7) | 175 (6.2) |
National policies/programs | 68 (55.7) | 28 (22.9) | 26 (21.3) | 122 (4.3) |
National Health Insurance | 59 (48.3) | 45 (36.8) | 18 (14.7) | 122 (4.3) |
Private insurance | 54 (63.5) | 18 (21.2) | 13 (15.3) | 85 (3.0) |
Cancer and environmental factors | 38 (58.4) | 26 (40.0) | 1 (1.5) | 65 (2.3) |
Occupational cancer | 13 (35.1) | 23 (62.1) | 1 (2.7) | 37 (1.3) |
Other | 58 (56.8) | 22 (21.6) | 22 (21.6) | 102 (3.6) |
Total | 1898 (67.6) | 659 (23.5) | 249 (8.9) | 2806 (100) |
Values are presented as number (%).
Values are presented as number (%).